| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Xu Cong Claire | Senior Vice President, Clinical Development Exhibit List: Ex. 24.1 - Power of Attorney | C/O NOVABRIDGE BIOSCIENCES,, 2440 RESEARCH BOULEVARD, SUITE 400, ROCKVILLE | /s/ Xi-Yong (Sean) Fu as attorney-in-fact | 18 Mar 2026 | 0002114309 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | NBP | Ordinary Shares | 288,266 | 18 Mar 2026 | Direct | F1, F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | NBP | 2021 Employee Share Option (right to buy) | 18 Mar 2026 | Ordinary Shares | 22,900 | $60.70 | Direct | F1, F3, F4 | ||||||
| holding | NBP | 2022 Employee Share Option (right to buy) | 18 Mar 2026 | Ordinary Shares | 43,690 | $21.15 | Direct | F1, F3, F5 | ||||||
| holding | NBP | 2023 Employee Share Option (right to buy) | 18 Mar 2026 | Ordinary Shares | 57,660 | $5.55 | Direct | F1, F3, F6 | ||||||
| holding | NBP | 2024 Employee Share Option (right to buy) | 18 Mar 2026 | Ordinary Shares | 146,865 | $1.74 | Direct | F1, F3, F7 | ||||||
| holding | NBP | 2024 Employee Share Option (right to buy) | 18 Mar 2026 | Ordinary Shares | 52,165 | $1.05 | Direct | F1, F3, F8 | ||||||
| holding | NBP | Restricted Share Units | 18 Mar 2026 | Ordinary Shares | 36,716 | Direct | F1, F3, F9 | |||||||
| holding | NBP | Restricted Share Units | 18 Mar 2026 | Ordinary Shares | 5,405 | Direct | F1, F3, F10 |
| Id | Content |
|---|---|
| F1 | The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. |
| F2 | Reported securities are represented by 123,594 ADSs. |
| F3 | Number of underlying securities and exercise price expressed in terms of ADSs. |
| F4 | The option was granted on July 21, 2021 and is fully vested and exercisable. |
| F5 | The option was granted on March 4, 2022 and is fully vested and exercisable. |
| F6 | The option was granted on January 4, 2023. The option vests and becomes exercisable in four equal annual installments beginning on the first anniversary of the grant date. |
| F7 | The option to purchase 195,820 ADSs was granted on May 30, 2024. The option vested or shall vest and become exercisable over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month. Amount of underlying securities excludes a portion of the option that has vested and been exercised. |
| F8 | The option was granted on September 3, 2024 and is fully vested and exercisable. Amount of underlying securities excludes a portion of the option that has vested and been exercised. |
| F9 | On May 30, 2024, the Reporting Person was granted 65,270 restricted share units ("RSUs"). Each RSU represents a contingent right to receive one ADS. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month. |
| F10 | On January 4, 2023, the Reporting Person was granted 21,620 RSUs. The RSUs vested or shall vest in four equal annual installments beginning on the first anniversary of the grant date. |
Senior Vice President, Clinical Development Exhibit List: Ex. 24.1 - Power of Attorney